Date:9/5/2012

-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2011 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc., its jointly owned subsidiary.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.

 

 

 

'/>"/>

SOURCE Isis Pharmaceuticals, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. Onyx Pharmaceuticals To Present At Upcoming Investor Conferences
2. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics: Twease.org
3. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
4. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals
5. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
6. Avanir Pharmaceuticals Reports Fiscal 2012 Third Quarter Financial And Business Results
7. Savient Pharmaceuticals Reports Second Quarter 2012 Financial Results
8. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
9. UCF nanoparticle discovery opens door for pharmaceuticals
10. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
11. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires